Calviri Launches Innovative Test for Early Detection of Canine Cancer

Calviri, Inc., a Phoenix-based biotechnology company dedicated to combating cancer in both dogs and humans, has announced significant advancements in cancer detection for canines. Their latest publication, titled "High-sensitivity multicancer detection of stage 1 cancer in dogs," appeared in the American Journal of Veterinary Research on June 17, 2025. This groundbreaking study highlights a novel diagnostic tool capable of detecting five major types of canine cancers—lymphoma, hemangiosarcoma, osteosarcoma, mast cell tumors, and soft tissue sarcomas—at their earliest stage, Stage 1.

Historically, most dogs are diagnosed with cancer only at later stages, when clinical symptoms become apparent, leading to treatment options that are often less effective. According to Dr. David Vail, DVM, Professor and Suran Distinguished Chair in Comparative Oncology at the University of Wisconsin, “Unfortunately, most aggressive cancer types that companion dogs develop present to clinical oncologists in later stages (2 or higher), when treatment options are limited and local control and cure are much more difficult. We know, just as it is the case in human oncology, that the earlier we can diagnose cancer, the more likely we can apply treatments that will result in long-term control and even cure.” This sentiment underscores the urgency for improved diagnostic measures that can detect tumors before they progress.

Calviri's innovative StageOne Plus test utilizes a unique technology that combines elements of semiconductor photolithography with peptide synthesis to create peptide chips, which can analyze a small blood sample for cancer biomarkers. This method marks a substantial advancement in early cancer detection technology, addressing the critical need for diagnostics that can identify Stage 1 tumors, which typically grow faster in dogs than in humans. This is particularly significant given that cancer accounts for approximately 50% of mortality in senior dogs. Stephen Albert Johnston, CEO of Calviri, expressed optimism about the potential impact of this diagnostic tool: “Calviri spent four years collecting the samples to enable developing this diagnostic test. We are very pleased our technology has broken the stage 1 sensitivity barrier for detecting dog cancers. Calviri wants to provide veterinarians and owners access to this new test to catch cancer at its earliest stage and help save pet lives.”

The company plans to launch the StageOne Plus test at a limited number of veterinary clinics starting in August 2025, with plans for broader availability as testing capacity increases. This initiative is not only anticipated to enhance the quality of veterinary care but also aims to alleviate the emotional and financial burdens associated with late cancer diagnosis in dogs.

In a broader context, the implications of such advancements extend beyond veterinary medicine; they could provide insights into cancer detection methodologies applicable to human oncology. By improving early-stage detection rates, both fields may benefit from enhanced treatment protocols and better patient outcomes. The ongoing research and developments by companies like Calviri represent a significant step forward in the fight against cancer, with the potential to save countless lives in both canine and human populations.

For more information, please visit www.Calviri.com.